Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension studyDavid Adams, Michael Polydefkis, Alejandra González‐Duarte et al.|The Lancet Neurology|2020Cited by 160
Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with PolyneuropathyLaura Obici, Conceição de Azevedo Coutinho, John L. Berk et al.|Neurology and Therapy|2023Cited by 21